Handelsbanken Fonder AB Decreases Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Handelsbanken Fonder AB lessened its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 41.3% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 193,119 shares of the medical equipment provider's stock after selling 135,747 shares during the quarter. Handelsbanken Fonder AB owned approximately 0.09% of Zimmer Biomet worth $23,503,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. American Century Companies Inc. boosted its holdings in Zimmer Biomet by 21.2% in the third quarter. American Century Companies Inc. now owns 4,863,741 shares of the medical equipment provider's stock worth $545,809,000 after acquiring an additional 852,186 shares in the last quarter. Boston Partners boosted its holdings in Zimmer Biomet by 29.2% in the third quarter. Boston Partners now owns 2,694,832 shares of the medical equipment provider's stock worth $302,366,000 after acquiring an additional 608,959 shares in the last quarter. Barclays PLC boosted its holdings in Zimmer Biomet by 129.2% in the third quarter. Barclays PLC now owns 1,072,494 shares of the medical equipment provider's stock worth $120,356,000 after acquiring an additional 604,652 shares in the last quarter. Qube Research & Technologies Ltd bought a new stake in Zimmer Biomet in the third quarter worth $57,972,000. Finally, Jupiter Asset Management Ltd. bought a new stake in Zimmer Biomet in the third quarter worth $50,763,000. Hedge funds and other institutional investors own 88.89% of the company's stock.

Zimmer Biomet Stock Performance

ZBH traded up $0.74 during midday trading on Tuesday, reaching $121.52. The company had a trading volume of 742,692 shares, compared to its average volume of 1,464,477. The company has a quick ratio of 0.78, a current ratio of 1.61 and a debt-to-equity ratio of 0.39. The business has a 50-day moving average of $126.19 and a two-hundred day moving average of $119.44. The company has a market cap of $24.97 billion, a P/E ratio of 24.85, a P/E/G ratio of 2.19 and a beta of 1.01. Zimmer Biomet Holdings, Inc. has a 1 year low of $102.00 and a 1 year high of $149.25.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its quarterly earnings results on Thursday, February 8th. The medical equipment provider reported $2.20 EPS for the quarter, topping analysts' consensus estimates of $2.15 by $0.05. The business had revenue of $1.94 billion during the quarter, compared to analysts' expectations of $1.93 billion. Zimmer Biomet had a return on equity of 12.79% and a net margin of 13.85%. The business's quarterly revenue was up 6.3% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.88 earnings per share. As a group, equities research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.07 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.79%. The ex-dividend date is Wednesday, March 27th. Zimmer Biomet's dividend payout ratio (DPR) is 19.63%.

Insider Transactions at Zimmer Biomet

In other news, VP Chad F. Phipps sold 26,156 shares of the firm's stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $128.62, for a total value of $3,364,184.72. Following the completion of the sale, the vice president now directly owns 44,145 shares of the company's stock, valued at approximately $5,677,929.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.70% of the company's stock.

Analyst Ratings Changes

Several research firms have commented on ZBH. Citigroup boosted their target price on Zimmer Biomet from $134.00 to $140.00 and gave the stock a "neutral" rating in a report on Wednesday, April 3rd. TheStreet upgraded Zimmer Biomet from a "c" rating to a "b-" rating in a research note on Thursday, February 8th. StockNews.com cut Zimmer Biomet from a "strong-buy" rating to a "buy" rating in a research note on Monday, February 19th. Raymond James boosted their price target on Zimmer Biomet from $133.00 to $137.00 and gave the stock an "outperform" rating in a research note on Wednesday, January 3rd. Finally, Truist Financial boosted their price target on Zimmer Biomet from $133.00 to $135.00 and gave the stock a "hold" rating in a research note on Friday, February 9th. One analyst has rated the stock with a sell rating, nine have given a hold rating and six have given a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $139.39.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.